Company Performance - Prestige Consumer Healthcare reported quarterly earnings of $0.95 per share, missing the Zacks Consensus Estimate of $1.01 per share, representing an earnings surprise of -5.94% [1] - The company posted revenues of $249.53 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.73%, compared to year-ago revenues of $267.14 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Prestige Consumer Healthcare shares have lost about 3.8% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $1.19 on revenues of $290.86 million, and for the current fiscal year, it is $4.76 on revenues of $1.15 billion [7] Industry Context - The Medical - Products industry, to which Prestige Consumer Healthcare belongs, is currently in the bottom 37% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5] - The unfavorable trend in estimate revisions prior to the earnings release has resulted in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]

ATS (ATS) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +11.11%. A quarter ago, it was expected that this automation services provider would post earnings of $0.26 per share when it actually produced earnings of $0.28, delivering a surprise of +7.69%. Over the last four quarters, th ...

Financial Performance - MariMed Inc. reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.01, representing an earnings surprise of +100.00% [1] - The company posted revenues of $39.61 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.91%, compared to year-ago revenues of $40.44 million [2] - Over the last four quarters, MariMed has surpassed consensus EPS estimates two times but has not beaten consensus revenue estimates [2] Stock Performance - MariMed Inc. shares have lost about 9.3% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The current status of estimate revisions translates into a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.01 on revenues of $42.9 million, and -$0.04 on revenues of $165.38 million for the current fiscal year [7] - The outlook for the industry can significantly impact stock performance, with the Medical - Products industry currently in the bottom 41% of Zacks industries [8]

Group 1 - Beyond Meat reported a quarterly loss of $0.43 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.37, but an improvement from a loss of $0.53 per share a year ago, indicating a surprise of -16.22% [1] - The company posted revenues of $74.96 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 8.31%, and down from $93.18 million year-over-year [2] - Beyond Meat shares have declined approximately 17.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] Group 2 - The earnings outlook for Beyond Meat is uncertain, with current consensus EPS estimates at -$0.33 on revenues of $77.57 million for the upcoming quarter, and -$1.73 on revenues of $303.64 million for the current fiscal year [7] - The Zacks Industry Rank places the Food - Meat Products sector in the bottom 21% of over 250 Zacks industries, suggesting that the industry's outlook could significantly impact stock performance [8] Group 3 - The estimate revisions trend for Beyond Meat was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] - Hormel Foods, a competitor in the same industry, is expected to report quarterly earnings of $0.41 per share, reflecting a year-over-year increase of 10.8%, with revenues projected at $2.97 billion, up 2.5% from the previous year [9][10]

Group 1 - The Pennant Group, Inc. reported quarterly earnings of $0.27 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, and showing an increase from $0.24 per share a year ago, resulting in an earnings surprise of +3.85% [1] - The company achieved revenues of $219.5 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.16%, and up from $168.74 million year-over-year [2] - The Pennant Group has outperformed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times in the same period [2] Group 2 - The stock has underperformed the market, losing about 16.3% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.28 on revenues of $215.51 million, and for the current fiscal year, it is $1.11 on revenues of $856.91 million [7] Group 3 - The Medical - Outpatient and Home Healthcare industry, to which The Pennant Group belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for The Pennant Group was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Company Performance - GoodRx Holdings, Inc. reported quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share, but showing an increase from $0.08 per share a year ago, resulting in an earnings surprise of -10.00% [1] - The company posted revenues of $203.07 million for the quarter ended June 2025, which was 1.03% below the Zacks Consensus Estimate and an increase from $200.61 million year-over-year [2] - Over the last four quarters, GoodRx has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - GoodRx shares have declined approximately 5.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for GoodRx is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $203.71 million, and for the current fiscal year, it is $0.38 on revenues of $819.58 million [7] - The trend of estimate revisions for GoodRx was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical Services industry, to which GoodRx belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

Group 1 - Catalyst Pharmaceutical (CPRX) reported quarterly earnings of $0.68 per share, exceeding the Zacks Consensus Estimate of $0.58 per share, and showing an increase from $0.56 per share a year ago, resulting in an earnings surprise of +17.24% [1] - The company achieved revenues of $146.56 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.30%, and up from $122.71 million in the same quarter last year [2] - Catalyst has consistently surpassed consensus EPS estimates for the last four quarters, indicating strong performance [2] Group 2 - The stock has gained approximately 6.5% since the beginning of the year, compared to the S&P 500's gain of 7.1%, suggesting a slight underperformance relative to the broader market [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The Zacks Rank for Catalyst is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Group 3 - The current consensus EPS estimate for the upcoming quarter is $0.56 on revenues of $138.29 million, while for the current fiscal year, the estimate is $2.25 on revenues of $559.96 million [7] - The Medical - Drugs industry, to which Catalyst belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Insights - Redwire Corporation reported a quarterly loss of $0.39 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.11, marking an earnings surprise of -254.55% [1] - The company's revenues for the quarter ended June 2025 were $61.76 million, missing the Zacks Consensus Estimate by 38.76%, and down from $78.11 million a year ago [2] - Redwire Corporation's shares have declined approximately 10.6% year-to-date, contrasting with the S&P 500's gain of 7.1% [3] Financial Performance - Over the last four quarters, Redwire Corporation has consistently failed to meet consensus EPS estimates [2] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $144.6 million, and for the current fiscal year, it is -$0.15 on revenues of $461.43 million [7] Industry Context - The Aerospace - Defense industry, to which Redwire Corporation belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Redwire's stock performance [5] Future Outlook - The estimate revisions trend for Redwire Corporation was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - Investors are encouraged to monitor changes in earnings estimates for the upcoming quarters and the current fiscal year [4][7]

Core Viewpoint - Curtiss-Wright reported quarterly earnings of $3.23 per share, exceeding the Zacks Consensus Estimate of $3.13 per share, and showing an increase from $2.67 per share a year ago, indicating a positive earnings surprise of +3.19% [1][2] Financial Performance - The company achieved revenues of $876.58 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.07%, and up from $784.79 million in the same quarter last year [2] - Over the last four quarters, Curtiss-Wright has consistently exceeded consensus EPS estimates and revenue estimates [2] Stock Performance - Curtiss-Wright shares have increased approximately 44.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.1% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $3.28, with expected revenues of $853.49 million, and for the current fiscal year, the EPS estimate is $12.77 on revenues of $3.4 billion [7] - The company's earnings outlook and estimate revisions will be crucial for future stock performance [4][6] Industry Context - The Aerospace - Defense Equipment industry, to which Curtiss-Wright belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, which may impact stock performance [8]

Group 1: Earnings Performance - Information Services Group (ISG) reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.07 per share, with an earnings surprise of +14.29% [1] - The company posted revenues of $61.57 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.66%, although this represents a decline from year-ago revenues of $64.26 million [2] - Over the last four quarters, ISG has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Group 2: Stock Performance and Outlook - ISG shares have increased approximately 27% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.1% [3] - The future performance of ISG's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $59.93 million, and for the current fiscal year, it is $0.29 on revenues of $239.96 million [7] Group 3: Industry Context - The Consulting Services industry, to which ISG belongs, is currently ranked in the top 12% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact ISG's stock performance [5]